Cargando…
Corrigendum to “A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial” [Int. Immunopharmacol. 96 (2021) 107743]
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280341/ https://www.ncbi.nlm.nih.gov/pubmed/34274220 http://dx.doi.org/10.1016/j.intimp.2021.107932 |
| _version_ | 1783722628709613568 |
|---|---|
| author | Sharma, Alok Shah, Mili Lakshmi, Satya Sane, Hemangi Captain, Jignasha Gokulchandran, Nandini Khubchandani, Pallavi Pradeep, M.K. Gote, Prakash Tuppekar, Balaji Kulkarni, Pooja Paranjape, Amruta Pradhan, Radhika Varghese, Ritu Kasekar, Sushil Nair, Vivek Khanbande, Ummeammara |
| author_facet | Sharma, Alok Shah, Mili Lakshmi, Satya Sane, Hemangi Captain, Jignasha Gokulchandran, Nandini Khubchandani, Pallavi Pradeep, M.K. Gote, Prakash Tuppekar, Balaji Kulkarni, Pooja Paranjape, Amruta Pradhan, Radhika Varghese, Ritu Kasekar, Sushil Nair, Vivek Khanbande, Ummeammara |
| author_sort | Sharma, Alok |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8280341 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82803412021-07-20 Corrigendum to “A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial” [Int. Immunopharmacol. 96 (2021) 107743] Sharma, Alok Shah, Mili Lakshmi, Satya Sane, Hemangi Captain, Jignasha Gokulchandran, Nandini Khubchandani, Pallavi Pradeep, M.K. Gote, Prakash Tuppekar, Balaji Kulkarni, Pooja Paranjape, Amruta Pradhan, Radhika Varghese, Ritu Kasekar, Sushil Nair, Vivek Khanbande, Ummeammara Int Immunopharmacol Corrigendum Published by Elsevier B.V. 2022-01 2021-07-15 /pmc/articles/PMC8280341/ /pubmed/34274220 http://dx.doi.org/10.1016/j.intimp.2021.107932 Text en © 2021 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Corrigendum Sharma, Alok Shah, Mili Lakshmi, Satya Sane, Hemangi Captain, Jignasha Gokulchandran, Nandini Khubchandani, Pallavi Pradeep, M.K. Gote, Prakash Tuppekar, Balaji Kulkarni, Pooja Paranjape, Amruta Pradhan, Radhika Varghese, Ritu Kasekar, Sushil Nair, Vivek Khanbande, Ummeammara Corrigendum to “A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial” [Int. Immunopharmacol. 96 (2021) 107743] |
| title | Corrigendum to “A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial” [Int. Immunopharmacol. 96 (2021) 107743] |
| title_full | Corrigendum to “A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial” [Int. Immunopharmacol. 96 (2021) 107743] |
| title_fullStr | Corrigendum to “A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial” [Int. Immunopharmacol. 96 (2021) 107743] |
| title_full_unstemmed | Corrigendum to “A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial” [Int. Immunopharmacol. 96 (2021) 107743] |
| title_short | Corrigendum to “A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial” [Int. Immunopharmacol. 96 (2021) 107743] |
| title_sort | corrigendum to “a pilot study for treatment of covid-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial” [int. immunopharmacol. 96 (2021) 107743] |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280341/ https://www.ncbi.nlm.nih.gov/pubmed/34274220 http://dx.doi.org/10.1016/j.intimp.2021.107932 |
| work_keys_str_mv | AT sharmaalok corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT shahmili corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT lakshmisatya corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT sanehemangi corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT captainjignasha corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT gokulchandrannandini corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT khubchandanipallavi corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT pradeepmk corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT goteprakash corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT tuppekarbalaji corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT kulkarnipooja corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT paranjapeamruta corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT pradhanradhika corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT vargheseritu corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT kasekarsushil corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT nairvivek corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 AT khanbandeummeammara corrigendumtoapilotstudyfortreatmentofcovid19patientsinmoderatestageusingintravenousadministrationofozonizedsalineasanadjuvanttreatmentregisteredclinicaltrialintimmunopharmacol962021107743 |